Tomek Szczudlo, VP, Global Medical Affairs, Franchise Head, Solid Tumors at Daiichi Sankyo, gives an overview of tenosynovial giant cell tumors (TGCT).
As Mr. Szczudlo explains, TGCT are a group of rare, benign tumors that involve the synovium, bursae and tendon sheath. While these tumors are benign, they can grow and cause extreme damage to the surrounding tissues. Joint pain, swelling, and decreased range in motion are all common symptoms of TGCT but these may be overlooked as being caused by more common conditions. The typical treatment for TGCT is surgical removal of the tumor but other options, such as the FDA-approved CSF1R inhibitor, pexidartinib, can be effective.
To learn more about TGCT, visit our TGCT Learning Center here.
